Novel Antibacterial and Antibiofilm Compounds Identified From Open Source Library Screening Against Priority Pathogen Acinetobacter Baumannii

Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro

“…In our study, 29 compounds at 10 μM inhibited A. baumannii , with nine of those compounds such as determined to be effective. Samoan et al screened Pandemic Response Box compounds, too, and identified antibacterial activity against A. baumannii, ATCC strain (19606 and BC-5) at 50 μM [ 29 ] and P. aeruginosa PAO1 at 20 μM, respectively [ 30 ]. Thirty pandemic response box compounds inhibited ATCC A. baumannii , and eleven compounds inhibited P. aeruginosa PAO1, respectively [ 29 , 30 ].…”

“…Samoan et al screened Pandemic Response Box compounds, too, and identified antibacterial activity against A. baumannii, ATCC strain (19606 and BC-5) at 50 μM [ 29 ] and P. aeruginosa PAO1 at 20 μM, respectively [ 30 ]. Thirty pandemic response box compounds inhibited ATCC A. baumannii , and eleven compounds inhibited P. aeruginosa PAO1, respectively [ 29 , 30 ]. It should be noted that the compounds, which inhibited the ATCC strain of A. baumannii in a previous study, were not inhibiting the clinical field isolate utilized in the current study [ 29 ].…”

“…Thirty pandemic response box compounds inhibited ATCC A. baumannii , and eleven compounds inhibited P. aeruginosa PAO1, respectively [ 29 , 30 ]. It should be noted that the compounds, which inhibited the ATCC strain of A. baumannii in a previous study, were not inhibiting the clinical field isolate utilized in the current study [ 29 ]. Despite showing robust activity in preliminary testing against both clinical pathogens, twenty compounds failed to reduce the bacterial survival on subsequent plating onto LB agar in the persister assay.…”